VIGL

VIGL

USD

Vigil Neuroscience Inc. Common Stock

$7.870+0.000 (0.000%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$7.870

High

$7.880

Low

$7.840

Volume

3.58M

Company Fundamentals

Market Cap

367.3M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.10M

Exchange

NMS

Currency

USD

52-Week Range

Low $1.312Current $7.870High $7.95

Related News

PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

View more
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

View more
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders
PR Newswire

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil Neuroscience, Inc. ...

View more
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm
GlobeNewswire

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative

View more
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

View more
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders
Analyst Upgrades

Stifel Downgrades Vigil Neuroscience to Hold, Lowers Price Target to $8

Stifel analyst Paul Matteis downgrades Vigil Neuroscience from Buy to Hold and lowers the price target from $11 to $8.

Analyst Upgrades

HC Wainwright & Co. Downgrades Vigil Neuroscience to Neutral, Lowers Price Target to $8

HC Wainwright & Co. analyst Andrew Fein downgrades Vigil Neuroscience from Buy to Neutral and lowers the price target from $14 to $8.